Thoma Bravo recently signaled to their LPs that the market has overreacted to the software downturn. Their thesis rests on a meaningful distinction: point solutions are dead, but “mission-critical” software with deep regulatory moats and zero-tolerance workflows is safe. They see a buying opportunity.
The thesis is not wrong about point solutions. It is wrong about what “mission-critical” actually protects.
The Mission-Critical Delusion
Mission-critical utility protects a workflow from elimination. It does not protect a seat-based pricing model from the compression that occurs when AI reduces the human labor required to operate that workflow.
Consider the evidence already in market. When AI agents handle 80% or more of tier-1 support tickets autonomously, a company does not need 100 Zendesk seats. It needs five, or a platform fee. The same dynamic applies to compliance platforms, ERP instances, and every other category Thoma Bravo is positioning as protected. A hospital will not replace its billing compliance system with an unproven chatbot. It will, however, eliminate the reconciliation headcount operating that system once AI agents can perform that reconciliation reliably.
This is the Biological Middleware problem in its most concentrated form. Across every function where reconciliation time has been specifically measured, knowledge workers spend a minimum of 30% of their time on manual data tasks rather than the work they were hired to do. Finance teams spend 30 to 50% of their time at month-end close on reconciliation. Data scientists spend 70% of their time on data preparation. These workers are not using mission-critical software to create value. They are using it to manually compensate for the failure of systems to interoperate.
When AI agents eliminate that layer, the seat count collapses regardless of how deeply embedded the underlying platform is.
The Arithmetic Thoma Bravo Is Not Running
The 1-to-4 Rule defines the margin discipline required in the RaaS era: for every $1 of AI infrastructure and compute spend, a vendor must capture at least $4 of Resolution Value to maintain the 75% gross margins that institutional investors require.
Seat-based pricing cannot satisfy this discipline as headcount declines. Consider a hypothetical mid-size enterprise managing global trade compliance across 130 applications, a figure consistent with documented SaaS stack sizes for firms of this scale. That firm currently pays $2 million annually for 500 seats. As they deploy AI agents to handle Atomic Resolutions autonomously, their active seat count compresses materially. Under seat-based pricing, the vendor’s revenue compresses proportionally. Under a RaaS model priced per Verified Compliance Resolution, the vendor captures the value of work performed rather than the count of people logged in, and the margin structure remains intact.
The vendors who survive this transition are not the ones with the deepest regulatory moats. They are the ones who reprice before compression forces their hand.
The Architecture Requirement
Repricing alone is insufficient. To deliver and bill for Atomic Resolutions, a vendor needs a unified, graph-structured data backbone capable of giving AI agents accurate, context-aware access to the full institutional logic of a customer’s environment. This is the High-Fidelity Repository, and it is the technical precondition for any credible RaaS pricing model.
Without it, a vendor is not selling resolutions. They are selling a slightly faster version of the same access model, now with AI features bolted on and margin compression accelerating.
The Prescription
Thoma Bravo’s portfolio companies should be running their ARR Risk Heat Map now. Any revenue line tied to mission-critical workflows that still prices by the seat is exposed to significant contraction at the next renewal cycle, not because the software becomes less essential, but because the headcount operating it continues to decline.
The buying opportunity Thoma Bravo sees is real. The protection they believe mission-criticality provides is not.